Akebia price target raised to $2 from $1.25 at H.C. Wainwright

H.C. Wainwright analyst Ed Arce raised the firm’s price target on Akebia Therapeutics to $2 from $1.25 and keeps a Neutral rating on the shares after the European Commission granted marketing authorization for Vafseo. The approval could be a key factor in partnership discussions, the analyst tells investors in a research note. However, the firm keeps a Neutral on the shares given the remaining uncertainty around vadadustat’s regulatory path in the U.S. and Vafseo’s time to market in the Europe.